These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23607364)

  • 1. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
    Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
    Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
    Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
    FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
    Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
    King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
    Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.
    Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y
    Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice.
    Hayward SL; Bautista-Lopez N; Suzuki K; Atrazhev A; Dickie P; Elliott JF
    J Immunol; 2006 Jun; 176(12):7715-25. PubMed ID: 16751419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice.
    Liu J; Purdy LE; Rabinovitch S; Jevnikar AM; Elliott JF
    Diabetes; 1999 Mar; 48(3):469-77. PubMed ID: 10078545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
    Verma B; Wesa A
    Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research.
    Holguin L; Echavarria L; Burnett JC
    J Virol; 2022 Feb; 96(3):e0139421. PubMed ID: 34818071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain.
    Rajagopalan G; Smart MK; Krco CJ; David CS
    J Immunol; 2002 Aug; 169(4):1774-83. PubMed ID: 12165499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9.
    Ka Y; Katano I; Nishinaka E; Welcker J; Mochizuki M; Kawai K; Goto M; Tomiyama K; Ogura T; Yamamoto T; Ito M; Ito R; Takahashi R
    Immunol Lett; 2021 Jan; 229():55-61. PubMed ID: 33253759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice.
    Abraham RS; Wilson SB; de Souza NF; Strominger JL; Munn SR; David CS
    Hum Immunol; 1999 Jul; 60(7):583-90. PubMed ID: 10426275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells.
    Zeng Y; Liu B; Rubio MT; Wang X; Ojcius DM; Tang R; Durrbach A; Ru Z; Zhou Y; Lone YC
    PLoS One; 2017; 12(4):e0173754. PubMed ID: 28399128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
    Eguren-Santamaria I; Fernández de Piérola E; Camps G; Martín-Muñoz P; Campos M; Cuculescu D; Aguilera-Buenosvinos I; Rodríguez López I; Salido-Vallejo R; Alexandru R; De Andrea CE; Álvarez-Gigli L; Berraondo P; Melero I; Sanmamed MF
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
    Covassin L; Jangalwe S; Jouvet N; Laning J; Burzenski L; Shultz LD; Brehm MA
    Clin Exp Immunol; 2013 Dec; 174(3):372-88. PubMed ID: 23869841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
    Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in mice.
    Søndergaard H; Kvist PH; Haase C
    Clin Exp Immunol; 2013 May; 172(2):300-10. PubMed ID: 23574326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.